Source: Annual Congress 2012 - Prognostic indices in respiratory infections
Disease area: Respiratory infections

Abstract

INTRODUCTION
To evaluate the prognostic value of biomarkers in community-acquired pneumonia (CAP), we studied the correlations between C-reactive protein (CRP), procalcitonin (PCT), leukocyte count (WBC) and proadrenomedulin (proADM) with the widely used PSI severity score.
MATERIAL AND METHODS
We prospectively studied 282 immunocompetent, adults patients hospitalized with CAP, calculated their PSI score and measured on admission the mentioned four blood biomarkers. Subsequently, we established the ROC curves to determine which of the biomarkers had a better discriminating power from mild CAP (PSI 1-3) to severe ones (PSI 4-5).
RESULTS
PCT and proADM significantly discriminated severe from mild CAP, although the area under curve was significantly higher for proADM (0.757 vs. 0.581). The other two biomarkers did not reach statistical significance.

CONCLUSIONS
ProADM is a good predictor of CAP severity at the time of admission, and can be useful, with the clinical scores to identify severe CAP. This may help us to make decisions of patients site of care and management in the early hours.

Rating:

Share or cite this content

Citations should be made in the following way:
S. Fandos, E. Minchole, A. Lasierra, A. Simon, C. Panadero, G. Hernandez, F. De Pablo, S. Garcia, C. Lapresta, S. Bello (Zaragoza, Spain). Biomarkers and severity in community-acquired pneumonia (CAP). Eur Respir J 2012; 40: Suppl. 56, 2525

Member's Comments

No comment yet.

Related content which might interest you: Biomarkers in community-acquired pneumonia (CAP) Source: Annual Congress 2012 - Respiratory infections: a clinical point of view Year: 2012 Biomarkers and community-adquired pneumonia (CAP) etiology Source: Annual Congress 2012 - Prognostic indices in respiratory infections Year: 2012 Validation of pneumonia severity models for healthcare-associated pneumonia (HCAP) Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 Atypical agents of community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 485s Year: 2003 Use of ceftriaxone/sulbactame for treatment of mild-to-severe community-acquired pneumonia (CAP) Source: Annual Congress 2009 - Treatment of airways disease Year: 2009 Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients Source: Annual Congress 2011 - COPD management Year: 2011 Community-acquired pneumonia (CAP): evaluation of severity criteria for hospitalization Source: Eur Respir J 2003; 22: Suppl. 45, 335s Year: 2003 Epidemiology of community-acquired pneumonia (CAP) Source: International Congress 2015 – Russia Day: Community-acquired pneumonia (CAP) in adults Year: 2015 Biomarkers for the prognostic assessment and disease severity evaluation in community-acquired pneumonia (CAP) Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Biomarkers and community acquired pneumonia (CAP) severity Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Biomarkers and community acquired pneumonia (CAP) severity Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Biomarkers and clinical stability in community-acquired pneumonia Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2007; 30: Suppl. 51, 42s Year: 2007 Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP) Source: International Congress 2014 – Respiratory infections: inflammation and treatment Year: 2014 Detection of liver function in patients with severe community-acquired pneumonia (CAP) Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 Severity assessment of healthcare-associated pneumonia and pneumonia in immunosuppression Source: Eur Respir J 2012; 40: 1201-1210 Year: 2012 Applicability of Fine criteria in patients hospitalized for community-acquired pneumonia (CAP) Source: Eur Respir J 2005; 26: Suppl. 49, 67s Year: 2005 Inflammatory biomarkers in predicting ICU admission of severe community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Pulmonary infections and sepsis Year: 2011 Etiology of community-acquired pneumonia (CAP) in young hospital patients Source: Eur Respir J 2002; 20: Suppl. 38, 356s Year: 2002 Prognostic factors of mortality in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 239s Year: 2003